Seeking Alpha: Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome) We report a rare case of Cushing’s syndrome in a pregnant woman carrying twins. Interestingly, the patient did exhibit many of the classic clinical features typically associated with hypercortisolism, ... Seeking Alpha: Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome) News-Medical.Net: Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing's syndrome and obesity Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing's syndrome and obesity Adult patients with Cushing syndrome who completed a 22-week trial of relacorilant therapy and continued treatment for 12 additional weeks preserved hypertension control and sustained other ...
Please provide your email address to receive an email when new articles are posted on . Adults with Cushing’s syndrome have a 78% higher risk for any cancer compared with controls. Cushing’s syndrome ...
